Amicus Therapeutics Inc (FOLD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amicus Therapeutics Inc (FOLD) has a cash flow conversion efficiency ratio of 0.059x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($16.25 Million) by net assets ($274.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Amicus Therapeutics Inc balance sheet quality to measure how much of total assets are equity-financed.
Amicus Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Amicus Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Amicus Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
Amicus Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amicus Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anhui Yingjia Distillery Co Ltd
SHG:603198
|
0.047x |
|
Shan XI Hua Yang Group New Energy Co Ltd
SHG:600348
|
0.020x |
|
Fortune Brands Innovations Inc.
NYSE:FBIN
|
-0.051x |
|
Perseus Mining Ltd
AU:PRU
|
0.078x |
|
JK Cement Limited
NSE:JKCEMENT
|
0.072x |
|
Global Power Synergy PCL
BK:GPSC
|
0.044x |
|
Dexus
AU:DXS
|
0.059x |
|
Valvoline Inc
NYSE:VVV
|
0.270x |
Annual Cash Flow Conversion Efficiency for Amicus Therapeutics Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Amicus Therapeutics Inc from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see Amicus Therapeutics Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $274.24 Million | $33.15 Million | 0.121x | +169.20% |
| 2024-12-31 | $194.04 Million | $-33.89 Million | -0.175x | +59.51% |
| 2023-12-31 | $160.17 Million | $-69.09 Million | -0.431x | +68.14% |
| 2022-12-31 | $123.05 Million | $-166.57 Million | -1.354x | -105.49% |
| 2021-12-31 | $307.37 Million | $-202.49 Million | -0.659x | +19.13% |
| 2020-12-31 | $286.38 Million | $-233.29 Million | -0.815x | -54.98% |
| 2019-12-31 | $476.43 Million | $-250.42 Million | -0.526x | +39.91% |
| 2018-12-31 | $342.91 Million | $-299.95 Million | -0.875x | -43.23% |
| 2017-12-31 | $352.85 Million | $-215.49 Million | -0.611x | -46.11% |
| 2016-12-31 | $360.15 Million | $-150.53 Million | -0.418x | -45.18% |
| 2015-12-31 | $347.83 Million | $-100.14 Million | -0.288x | +31.92% |
| 2014-12-31 | $122.18 Million | $-51.67 Million | -0.423x | +57.75% |
| 2013-12-31 | $45.75 Million | $-45.79 Million | -1.001x | -105.33% |
| 2012-12-31 | $69.22 Million | $-33.74 Million | -0.487x | +70.81% |
| 2011-12-31 | $29.59 Million | $-49.42 Million | -1.670x | -675.56% |
| 2010-12-31 | $64.93 Million | $-13.98 Million | -0.215x | +64.33% |
| 2009-12-31 | $71.83 Million | $-43.37 Million | -0.604x | -16.36% |
| 2008-12-31 | $71.04 Million | $-36.86 Million | -0.519x | -452.81% |
| 2007-12-31 | $103.30 Million | $15.19 Million | 0.147x | -66.36% |
| 2006-12-31 | $-77.52 Million | $-33.89 Million | 0.437x | -13.57% |
| 2005-12-31 | $-35.83 Million | $-18.12 Million | 0.506x | -- |
About Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha … Read more